Our partner is focused on developing cellular immunotherapies for cancer and immune disorders. Their innovative approach uses induced pluripotent stem cell technology to create off-the-shelf, genetically engineered cell therapies, aiming to improve patient outcomes with more effective and accessible treatments.

This critical hire led and grew an established team and drove the success of this company. They led process technology and developed sustainable platforms. They defined, refined, and drove MSAT strategy, and developed scalable commercial manufacturing processes. They also developed best practices in identifying, evaluating, selecting, and managing Contract Manufacturing Organizations.